| 36417-90-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• CAS: 36417-90-0
• 化学式: C16H18N2NaO7S2
• 分子量: 437.4
• InChiKey: DGMOWYXFFHYUJF-YWUHCJSESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.13
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  175
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Pharmaceutical preparation containing copolyvidone
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10098866B2

  公开（公告）日：2018-10-16

  A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.

  一种稳定的制剂，包括：在聚乙二醇含制剂中的不稳定药物；以及一种包衣剂，其包衣剂包括一种共聚维酮，而不是用聚乙二醇包衣药物。
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20170015655A1

  公开（公告）日：2017-01-19

  The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供一种具有HDAC抑制作用的杂环化合物，用于治疗自身免疫疾病和/或炎症性疾病、移植物抗宿主病、癌症、包括神经退行性疾病、沙科-玛丽-图特病等在内的中枢神经疾病，以及包含该化合物的药物组合物。本发明涉及一种由下式（I）表示的化合物： 其中每个符号如规范中定义，或其盐。
• External preparation for skin diseases containing nitroimidazole
  申请人：——

  公开号：US20030092754A1

  公开（公告）日：2003-05-15

  An external preparation for skin disease which comprises a nitroimidazole derivative represented by the following formula (I): 1 wherein R 1 , R 3 and R 4 may be the same or different and represent a hydrogen atom, a nitro group, a lower alkyl group, a substituted lower alkyl group, a lower alkenyl group, or a substituted lower alkenyl group; and R 2 represents a hydrogen atom, a lower alkyl group, a substituted lower alkyl group and a lower alkenyl group or a substituted lower alkenyl group, provided that any one of R 1 , R 3 and R 4 is a nitro group.

  一种外用制剂，用于皮肤疾病，包括以下式(I)所代表的硝基咪唑衍生物：1其中R1、R3和R4可以相同也可以不同，并表示氢原子、硝基、低烷基、取代的低烷基、低烯基或取代的低烯基；R2表示氢原子、低烷基、取代的低烷基和低烯基或取代的低烯基，只要R1、R3和R4中的任何一个是硝基。
• AZITHROMYCIN-CONTAINING AQUEOUS PHARMACEUTICAL COMPOSITION AND A METHOD FOR THE PREPARATION OF THE SAME
  申请人：SUZUKI Hidekazu

  公开号：US20070087980A1

  公开（公告）日：2007-04-19

  The invention provides an azithromycin-containing aqueous pharmaceutical composition, which comprises at least one member selected from the group consisting of azithromycin, its anhydride, its hydrate, and pharmaceutically acceptable salts thereof, and at least one member selected from the group consisting of monoethanolamine, diethanolamine, triethanolamine, amino acid, ethylenediaminetetraacetic acid, and pharmaceutically acceptable salts thereof, and which does not comprise boric acid or pharmaceutically acceptable salts thereof, and a method for the preparation of the composition, wherein an azithromycin-containing liquid is maintained at pH of 4.0 or higher throughout the method for the preparation. The composition has good heat and storage stability.

  本发明提供一种含有阿奇霉素的水性制药组合物，包括从以下组中选择的至少一种成员：阿奇霉素、其无水物、其水合物和其药学上可接受的盐，以及从以下组中选择的至少一种成员：单乙醇胺、双乙醇胺、三乙醇胺、氨基酸、乙二胺四乙酸和药学上可接受的盐，且不含硼酸或其药学上可接受的盐。本发明还提供一种制备该组合物的方法，其中阿奇霉素含液在制备过程中的pH值保持在4.0或更高。该组合物具有良好的热稳定性和储存稳定性。
• Release-Control Composition
  申请人：Ishida Hajime

  公开号：US20090053308A1

  公开（公告）日：2009-02-26

  The present invention relates to a controlled release capsule preparation for oral administration, which contains (i) a granule containing a physiologically active substance which is a compound represented by the formula: wherein n is an integer of 1 to 3, and Ar is an aromatic ring optionally having substituent(s), or a salt thereof, and a hydrophilic polymer, and coated with an enteric coating agent and the like, and (ii) a fluidizer. According to the present invention, a controlled release composition for oral administration of an imidazole derivative, which has steroid C 17,20 -lyase inhibiting activity and which has remarkably improved sustainability of the blood concentration, is provided.

  本发明涉及一种口服控释胶囊制剂，其包含（i）一种颗粒，其中包含一种生理活性物质，该物质是由以下公式表示的化合物：其中n是1至3的整数，Ar是一种芳香环，可以具有取代基，或其盐，以及一种亲水性聚合物，并涂有肠溶涂层剂等；（ii）一种流动剂。根据本发明，提供了一种具有类固醇C17,20-裂解酶抑制活性并具有显着改善血浓度持久性的咪唑衍生物口服控释组合物。